Leukemias are cancers that begin in cells that normally develop into various types of blood cells. Most leukemias begin in the early stages of white blood cells, but some leukemias begin in other types of blood cells.
Acute lymphocytic leukaemia (ALL) is a type of leukaemia that is also known as acute lymphoblastic leukaemia. The term “acute” refers to the fact that the leukaemia can progress quickly and, if left untreated, will most likely be fatal within a few months. The term “lymphocytic” refers to the fact that it develops from early (immature) forms of lymphocytes, a type of white blood cell.
Everything begins in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most of the time, leukaemia cells infiltrate the bloodstream quickly.
Chemotherapy (chemo) is the application of drugs to the treatment of cancer. Chemotherapeutic drugs travel through the bloodstream to reach cancer cells throughout the body. Chemotherapy is therefore useful for cancers that have spread throughout the body, such as leukaemia.
Drugs used in targeted therapy work by attacking specific parts of cancer cells. They are not the same as standard chemotherapy (chemo) drugs. They occasionally work when chemo does not, and they frequently have different side effects. Some of these medications may be beneficial in certain cases of acute lymphocytic leukaemia (ALL).
Immunotherapy is the use of medications to assist a patient’s immune system in more effectively recognising and destroying cancer cells. Certain types of immunotherapies are now being used to treat acute lymphocytic leukaemia (ALL).
In the treatment of ALL, surgery plays a very limited role. Because leukaemia cells spread so widely throughout the bone marrow and blood, surgery cannot cure this type of cancer. Surgery, with the exception of a possible lymph node biopsy, is rarely used in the diagnosis of ALL, as this is typically done with a bone marrow aspiration and biopsy.
Radiation treatment is similar to getting an x-ray, except that the radiation is much stronger. The procedure is completely painless. Each treatment is only a few minutes long, but the setup time in getting you into position for treatment – is usually longer. The number of treatments you receive is determined by the reason radiation therapy is used.
A stem cell transplant (SCT) allows doctors to use higher doses of chemotherapy (sometimes with radiation) to kill cancer cells. Following the completion of these treatments, the patient receives an infusion of blood-forming stem cells to restore their bone marrow.
Treatment is usually divided into three stages:
Diarrhoea antibiotic shows potential in treating aggressive blood cancer
A form of aggressive blood cancer might be found to be more sensitive to chemotherapy with the use of an antibiotic currently available for treating diarrhoea, as per novel research published in Science Translational Medicine. The study was funded by Cancer Research UK and Blood Cancer UK, the study looked to tackle a certain type of acute myeloid leukaemia of which contains a genetic modification called MLL, thorough investigations on cancer’s origins.
This form of leukaemia, often called MLL-AML, has a peculiarly poor prognosis as it suddenly turns resistant to standard chemotherapies. Resolving this resistance had proven to be a major challenge in treating this cancer, and has left patients with no other alternative.
Even the best cancer doctors in Delhi concur on the fact that resistance to treatments is the biggest challenge cancer research faces and coming to terms with the fact that there is no other treatment available is undeniably the worst thing a doctor wants to tell their patient. These recent findings demonstrate how unravelling the biology of cancer has lead to new discoveries, and how we could already have a huge array of drugs out there that could help boost the effects of current treatments.
Acute myeloid leukaemia is a variegated disease, with different sub-types dependent on the genetic mutations that are causing it. This affects how successfully the cancer is treated, with some sub-types having a far poorer prognosis than others. MLL-AML is deadly, with only 1 in 4 patients surviving for 2 to 5 years or so.
The researchers observed how MLL-AML developed in humans for the first time, through establishing a new way of modelling how the stem cells that make our blood could turn into AML when altered by the MLL genetic alteration.
It’s a significant moment for cancer treatment across the world.
After the research that threw light on the origins of MLL leukaemia in mice almost 18 years ago, this development is an important milestone for AML research and provides a new way for screening and identifying new targets to treat.
Using this new approach, the team found that the disease could actually originate from 2 different types of cells, with one causing more resistant disease than the other.
Studying the more resistant type in detail revealed it produced way more of a particular protein – ABCC3 – than the other one, and this could be responsible for making it more resistant to chemotherapy.
When this theory was confirmed in human cells: the team got rid of the cell’s ability to produce any more ABCC3, and it was far more sensitive to chemotherapy.
The next step forward was finding a drug that could stop ABCC3 from being produced or prevent it from working at all. By researching, the team found a paper that showed fidaxomicin – an antibiotic prescribed to treat diarrhoea caused by the bacteria C. difficile – was rather effective for inhibiting ABCC3.
This was unexpected and, actually fortuitous, that there was a recent study showing an already approved antibiotic could work for this research. Testing the drug for the treatment of resistant MLL-AML, the team found it successfully sensitised cancer to chemotherapy in both the cells grown in the lab and in mice.
This is hugely promising and now we need to do further studies and testing with this approach in people with AML and see how many benefits it brings.